CAR-T

Patient Story: CAR-T Therapy Brings New Hope for Lymphoma Patients – A Case from a Chinese Hospital

**Patient Story: CAR-T Therapy Brings New Hope for Lymphoma Patients – A Case from a Chinese Hospital** In the field of cancer treatment, China has achieved groundbreaking success with CAR-T cell therapy, especially in treating relapsed or refractory lymphoma. Today, we share the story of one patient whose life was transformed through this revolutionary treatment Read More

November 12th,2024 patient story , CAR-T , Lymphoma

China’s CAR-T Therapy Emerging in Glioma Treatment: Neurosurgery Team Wins Three International Awards

**China’s CAR-T Therapy Emerging in Glioma Treatment: Neurosurgery Team Wins Three International Awards** At the recently concluded 76th International Exhibition of Ideas, Inventions, and New Products (IENA) in Nuremberg, Germany, a Chinese neurosurgery research team achieved remarkable success. Their independently developed project, the “Fourth-Generation Dual-Target Optimized CAR-T Cell Therapy Platform for Neuro-oncology,” stood out among Read More

November 10th,2024 CAR-T , Solid tumor

Exceptional Efficacy of CAR-T Therapy in China: Disease Control Rate for Advanced Liver Cancer Reaches 78% to 91.3%

### Exceptional Efficacy of CAR-T Therapy in China: Disease Control Rate for Advanced Liver Cancer Reaches 78% to 91.3% #CARTTherapy #LiverCancer #SolidTumors In recent years, China has made remarkable advances in CAR-T cell therapy, particularly demonstrating exceptional potential in liver cancer treatment. CAR-T cell therapy, or chimeric antigen receptor T-cell therapy, involves genetically engineering a Read More

November 8th,2024 Solid tumor , CAR-T

New Breakthrough in CAR-T Cell Research in China: Type 2 T Cell Function Supports Long-term Leukemia Remission

#### New Breakthrough in CAR-T Cell Research in China: Type 2 T Cell Function Supports Long-term Leukemia Remission #CAR-T #Leukemia #Type2TCells #ALL #GATA3 In recent years, China has achieved significant progress in CAR-T cell therapy, particularly in treating acute lymphoblastic leukemia (ALL). CD19-targeted CAR-T cell therapy has provided new hope for curing patients with relapsed or refractory Read More

November 7th,2024 Leukemia , CAR-T

**Patient Story | Chinese CAR-T Therapy: An Inspiring Journey of Changing Fate for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)**

**Patient Story | Chinese CAR-T Therapy: An Inspiring Journey of Changing Fate for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)** #CAR-T #DLBCL #Lymphoma #CARTtherapy #RRDLBCL #Patientstory #CD19 In the field of cancer treatment, China has made remarkable strides in CAR-T cell therapy, especially in the fight against relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL). Read More

November 7th,2024 CAR-T , Lymphoma , patient story

APBMT 2024丨Global Breakthrough of Chinese CAR-T Therapy: New Advances in the Treatment of Central Nervous System Lymphoma (CNSL)

### APBMT 2024丨Global Breakthrough of Chinese CAR-T Therapy: New Advances in the Treatment of Central Nervous System Lymphoma (CNSL) #CAR-T #CNSL #ASCT #APBMT2024 #CARTtherapy #CentralNervousSystemLymphoma #Lymphoma #RRCNSL #APBMT In the treatment of relapsed or refractory central nervous system lymphoma (R/R CNSL), Chinese CAR-T therapy is pioneering new directions worldwide. Conventional treatments for this disease have shown limited effectiveness, particularly when autologous stem Read More

November 7th,2024 CAR-T , Lymphoma

The World’s First! China’s Non-Viral Site-Specific Integrated PD1-CAR-T Therapy Brings New Hope for Systemic Lupus Erythematosus(SLE) Patients

**The World’s First! China’s Non-Viral Site-Specific Integrated PD1-CAR-T Therapy Brings New Hope for Systemic Lupus Erythematosus(SLE) Patients** #PD1 #CART #SLE #SystemicLupusErythematosus #Lupus #CARTTherapy #BRL203 #Nature In November 2024, Chinese gene and cell therapy company BRL Medicine announced that its self-developed non-viral site-specific integrated PD1-CAR-T therapy, “BRL-203,” has received clinical trial approval from the National Medical Products Administration (NMPA) of Read More

November 6th,2024 CAR-T

Groundbreaking Chinese CAR-T Research: CD5 CAR-T Therapy Brings New Hope for Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL)

Groundbreaking Chinese CAR-T Research: CD5 CAR-T Therapy Brings New Hope for Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) Relapsed or refractory acute T-cell lymphoblastic leukemia (r/r T-ALL) has long lacked effective treatment options, with a poor prognosis. Although CD7 CAR-T therapy has shown some efficacy, many patients experience relapse due to CD7 antigen loss. #CAR-T #TALL #ALL #CARTtherapy #leukemia Read More

November 6th,2024 Leukemia , CAR-T

Breakthrough in China’s CAR-T Therapy for Treating Relapsed B-ALL: Donor-Derived CD19 CAR-T Shows Long-Term Survival Advantage

**Breakthrough in China’s CAR-T Therapy for Treating Relapsed B-ALL: Donor-Derived CD19 CAR-T Shows Long-Term Survival Advantage** #CAR_TTherapy #B_ALL #DonorCAR_T #CAR_T #ALL #ChinaCART #CD19 #alloHSCT In recent years, China has made significant strides in CAR-T cell therapy, particularly in treating B-cell acute lymphoblastic leukemia (B-ALL). Donor-derived CAR-T therapy has shown promising efficacy for B-ALL patients who Read More

November 6th,2024 Leukemia , CAR-T

The Rise of China’s CAR-T Therapy: New Hope for Multiple Myeloma Patients

**The Rise of China’s CAR-T Therapy: New Hope for Multiple Myeloma Patients** #CARTTherapy #CART #MultipleMyeloma #BloodCancer #patientstory China’s CAR-T cell therapy has emerged as a highly effective and proactive option for treating relapsed and refractory multiple myeloma, bringing new hope to patients facing limited treatment options. This innovative therapy has shown significant effectiveness in clinical Read More

November 5th,2024 Myeloma , CAR-T , patient story

China Overcomes Solid Tumor Challenge: CAR-T Technology IM96 Leads Innovation in Colorectal Cancer Treatment

**China Overcomes Solid Tumor Challenge: CAR-T Technology IM96 Leads Innovation in Colorectal Cancer Treatment** #IM96 #CART #ColorectalCancer #CARTtherapy #ESMO #2024ASCO #SolidTumor China has made remarkable progress in the field of innovative cancer treatment. In October 2024, a Chinese biotechnology company announced that IM96 CAR-T cell injection, developed in collaboration with Peking University Cancer Hospital, received clinical trial approval from the Read More

November 5th,2024 Solid tumor , CAR-T

CAR-T Cell Therapy as a New Option for Treating Multiple Myeloma

**CAR-T  Cell Therapy as a New Option for Treating Multiple Myeloma** “CAR-T cell therapy has now become a new option for treating patients with relapsed and refractory multiple myeloma, with hopes of changing the difficult situation in myeloma treatment where treatments are either ineffective or unavailable,” said Jin Jie, Director of the Hematology Department at the Read More

November 4th,2024 Myeloma , CAR-T